Tamoxifen for the prevention of breast cancer

European Journal of Cancer

Volumn 36, Issue 2, 2000, Pages 142-145

  Powles, T J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PREVENTION; CLINICAL TRIAL; ENDOMETRIUM CANCER; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0033977010     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00269-5     Document Type: Article

References (7)

1. Gail M., Brintom L., Byar D.et al. Projecting individualised probabilities of developing breast cancer for white females who are examined annually. J. Natl. Cancer Inst. 81:1989;1879-1886.
2. Tokunago M., Norman J., Asano M.et al. Malignant breast tumours among atomic bomb survivors. J. Natl. Cancer Inst. 62:1979;1347-1359.
3. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
4. Love R., Newcomb P., Wiebe D.et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J. Natl. Cancer Inst. 82:1990;1327-1332.
5. Chlebowski R., Collyar D., Somerfield M., Pfister D. American Society of Clinical Oncology. technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene J. Clin. Oncol. 17:1999;1939-1955.
6. Powles T. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 91(8):1999;730.
7. Osin P., Crook T., Powles T., Gusterson B. Hormone status of in situ cancer in BRCA1/BRCA2 mutation carriers. Lancet. 351:1998;1487.